Pre-made Gontivimab benchmark antibody ( Bispecific Single Domains (VH-VH'-VH'), anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-251
Pre-made Gontivimab benchmark antibody (Bispecific Single Domains (VH-VH'-VH'), anti-RSV gpF therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Gontivimab is a monoclonal antibody-derived therapeutic protein (Nanobodies®) (designated as ALX 0171), being developed by Ablynx (a subsidiary of Sanofi) as a once-daily treatment of patients with respiratory syncytial virus (RSV) infections.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Gontivimab biosimilar, Bispecific Single Domains (VH-VH'-VH’): Anti-RSV gpF therapeutic antibody|
|Format||Bispecific Single Domains (VH-VH'-VH')|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Discontinued||Respiratory syncytial virus infections|